Success Metrics

Clinical Success Rate

100.0%

Based on 9 completed trials

Completion Rate

100%(9/9)

Active Trials

0(0%)

Results Posted

11%(1 trials)

Phase Distribution

Ph phase_3

33%

Ph phase_4

33%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 2Efficacy & side effects

3(33.3%)

Phase 3Large-scale testing

3(33.3%)

Phase 4Post-market surveillance

3(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 23 (33.3%)

Phase 33 (33.3%)

Phase 43 (33.3%)

Trials by Status

completed9100%

Recent Activity

0 active trials

Showing 5 of 9

completedphase_3

Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children

NCT00840801

completedphase_2

FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years

NCT00161850

completedphase_2

FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years

NCT00161889

completedphase_4

Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years

NCT00161954

completedphase_2

Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years

NCT00161746

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT00840801Phase 3

Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children

Completed

NCT00161850Phase 2

FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years

Completed

NCT00161889Phase 2

FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years

Completed

NCT00161954Phase 4

Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years

Completed

NCT00161746Phase 2

Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years

Completed

NCT00161876Phase 3

FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years

Completed

NCT00161824Phase 3

Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR

Completed

NCT00161967Phase 4

TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)

Completed

NCT00503529Phase 4

TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)

Completed

All 9 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 9